FY2026 EPS Forecast for Oncolytics Biotech Cut by Analyst

Oncolytics Biotech Inc. (TSE:ONC) – Equities researchers at Zacks Research cut their FY2026 earnings per share (EPS) estimates for shares of Oncolytics Biotech in a research note issued to investors on Thursday, August 27th. Zacks Research analyst D. Bautz now forecasts that the company will post earnings of ($0.37) per share for the year, down from their previous forecast of ($0.33). The consensus estimate for Oncolytics Biotech’s current full-year earnings is ($0.41) per share.

Oncolytics Biotech Price Performance

Oncolytics Biotech stock opened at C$14.90 on Wednesday. Oncolytics Biotech has a 52-week low of C$0.44 and a 52-week high of C$2.08. The company’s 50 day moving average is C$14.90 and its two-hundred day moving average is C$14.90. The company has a quick ratio of 8.86, a current ratio of 2.88 and a debt-to-equity ratio of 14.58. The firm has a market cap of C$1.50 billion, a PE ratio of -40.27 and a beta of 0.80.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc to co-develop pelareorep, as well as with Roche Holding AG.